Black Cohosh Drug Interactions: Tamoxifen, CYP2D6, and More
Black cohosh is primarily used by women navigating perimenopause and menopause for symptom relief — hot flashes, night sweats, mood changes. Many women in this age group are also managing breast cancer or are in active treatment or post-treatment follow-up, which is exactly where the interaction concern becomes clinically relevant. Black cohosh inhibits CYP2D6, an enzyme that plays a critical role in tamoxifen's conversion to its active form, and that inhibition may reduce tamoxifen's ability to prevent cancer recurrence.
The tamoxifen–endoxifen connection
Tamoxifen itself is not the pharmacologically active agent — it is a prodrug that the body must convert to endoxifen, its primary active metabolite, to achieve meaningful anti-estrogenic effects in breast tissue. That conversion is carried out almost entirely by CYP2D6, a liver enzyme that varies substantially in activity between individuals based on genetic polymorphisms. People who are CYP2D6 poor metabolizers produce far less endoxifen and tend to have worse outcomes on tamoxifen than extensive metabolizers — the clinical data supporting this relationship are reasonably consistent.
Black cohosh inhibits CYP2D6. By reducing the enzyme's activity, it slows the conversion of tamoxifen to endoxifen, potentially pushing someone who would otherwise have adequate CYP2D6 activity into a functional state closer to a poor metabolizer. Whether this translates to meaningfully lower endoxifen concentrations in a given patient depends on the dose of black cohosh, baseline CYP2D6 phenotype, and tamoxifen dose — but the directional effect is clearly unfavorable. NCCIH flags this interaction and notes that black cohosh may interact with hormone-sensitive conditions and treatments.
This same CYP2D6 inhibition is also relevant for other medications metabolized by this enzyme — certain antidepressants (fluoxetine, paroxetine, tricyclics), opioid analgesics like codeine and tramadol (which require CYP2D6 conversion for analgesia), antiarrhythmics, and antipsychotics. Reduced CYP2D6 activity from black cohosh could raise plasma levels of some drugs (those where the parent compound is active and CYP2D6 handles elimination) while reducing efficacy for prodrugs like tamoxifen and codeine where the enzyme creates the active form.
Hormone-sensitive conditions and broader context
Beyond CYP2D6, black cohosh has historically been studied — and marketed — for estrogen-like effects, though the evidence for genuine estrogenic activity is mixed. Earlier research suggested possible SERM (selective estrogen receptor modulator) activity; more recent work using binding assays and tissue studies has cast doubt on whether black cohosh directly activates estrogen receptors. NCCIH currently notes that the mechanism of any hormonal effects is unclear.
For people with hormone-receptor-positive breast cancer on tamoxifen or aromatase inhibitors (letrozole, anastrozole, exemestane), the uncertainty itself is a reason for caution — not because estrogen receptor agonism is proven, but because the stakes of getting it wrong in an active treatment context are high. Aromatase inhibitors are not CYP2D6-dependent and would not be affected by that specific mechanism, but the broader question of whether any supplement exerts hormonally relevant effects is worth discussing with an oncologist rather than deciding unilaterally.
The practical guidance from NCCIH is clear: people with hormone-sensitive conditions or taking hormone-modulating treatments should discuss black cohosh use with their healthcare provider before starting it. The alternative symptom relief options for menopause symptoms during cancer treatment — including non-hormonal pharmacological options — are worth exploring with the oncology team.